» Articles » PMID: 29620670

Effectiveness of Multiple Therapeutic Strategies in Neovascular Glaucoma Patients: A PRISMA-compliant Network Meta-analysis

Overview
Specialty General Medicine
Date 2018 Apr 6
PMID 29620670
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Neovascular glaucoma (NVG) is a severe secondary glaucoma with uncontrolled intraocular pressure that leads to serious eye pain and vision loss. Presently, the therapeutic strategies for NVG are diverse, but the therapeutic effects are still not ideal. We performed a network analysis to assess the effect of multiple therapeutic strategies on the treatment of NVG patients.

Methods: We searched public electronic databases through April 2017 using the following keywords "neovascular glaucoma," "iris neovascularization," "hemorrhagic glaucoma," and "random" without language restrictions. The outcome considered in the present analysis was treatment success rate. A network meta-analysis and multilevel mixed-effects logistic regression were used to compare regimens.

Results: We included 27 articles assessing a total of 1884 NVG patients in our analysis. According to the network analysis, interferon and mitomycin plus trabeculectomy (94.9%), glaucoma valve implantation (86.9%), and iris photocoagulation plus trabeculectomy (81.9%) were the most likely to improve treatment success rate in NVG patients. The multilevel logistic regression analysis showed that glaucoma valve, bevacizumab, interferon, cyclophotocoagulation, trabeculectomy, iris photocoagulation, ranibizumab, and mitomycin had advantages in terms of improving treatment success rate in NVG patients. However, the application of retinal photocoagulation and vitrectomy reduced patient treatment success rate.

Conclusion: The regimen including mitomycin, interferon, and trabeculectomy was the most likely to improve the treatment success rate in NVG patients. The application of glaucoma valve and bevacizumab were more beneficial for improving patient treatment success rate as a surgery and as an agent, respectively.

Citing Articles

Comparative efficacy and safety of different anti-VEGF agents combined with different delivery methods for neovascular glaucoma: a systematic review and Bayesian network meta-analysis.

Wang J, Guo Y, Wei J, Min J, Ye L BMJ Open. 2024; 14(3):e080103.

PMID: 38443085 PMC: 11146364. DOI: 10.1136/bmjopen-2023-080103.


Anti-vascular endothelial growth factor for neovascular glaucoma.

Rittiphairoj T, Roberti G, Michelessi M Cochrane Database Syst Rev. 2023; 4:CD007920.

PMID: 37010901 PMC: 10069372. DOI: 10.1002/14651858.CD007920.pub4.


Comparisons of the short-term effectiveness and safety of surgical treatment for neovascular glaucoma: a systematic review and network meta-analysis.

Lin P, Zhao Q, He J, Fan W, He W, Lai M BMJ Open. 2022; 12(5):e051794.

PMID: 35613778 PMC: 9131079. DOI: 10.1136/bmjopen-2021-051794.


Downregulation of angiogenic factors in aqueous humor associated with less intraoperative bleeding in PDR patients with NVG receiving conbercept: a randomized controlled trial.

Xu Q, Gong C, Qiao L, Feng R, Liu H, Liu Y BMC Ophthalmol. 2022; 22(1):224.

PMID: 35585570 PMC: 9115965. DOI: 10.1186/s12886-022-02451-6.


Simultaneous pars plana vitrectomy, panretinal photocoagulation, cryotherapy, and Ahmed valve implantation for neovascular glaucoma.

Bernal-Morales C, Dotti-Boada M, Olate-Perez A, Navarro-Angulo M, Pelegrin L, Figueras-Roca M Int J Ophthalmol. 2021; 14(9):1396-1401.

PMID: 34540616 PMC: 8403848. DOI: 10.18240/ijo.2021.09.15.


References
1.
Zhang M, Li B, Sun Y . EX-PRESS and ahmed glaucoma valve in treatment of refractory glaucoma. Acta Ophthalmol. 2015; 94(5):e382-3. DOI: 10.1111/aos.12898. View

2.
SooHoo J, Seibold L, Kahook M . Recent advances in the management of neovascular glaucoma. Semin Ophthalmol. 2013; 28(3):165-72. DOI: 10.3109/08820538.2012.730103. View

3.
Brar V, Sharma R, Murthy R, Chalam K . Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis. 2010; 16:1848-53. PMC: 2956671. View

4.
Vermunt J . Mixed-Effects Logistic Regression Models for Indirectly Observed Discrete Outcome Variables. Multivariate Behav Res. 2016; 40(3):281-301. DOI: 10.1207/s15327906mbr4003_1. View

5.
Arcieri E, Paula J, Jorge R, Barella K, Arcieri R, Secches D . Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up. Acta Ophthalmol. 2014; 93(1):e1-6. DOI: 10.1111/aos.12493. View